Literature DB >> 22946776

Soluble CD163 is associated with body mass index and blood pressure in hypertensive obese Saudi patients.

Nasser M Al-Daghri1, Omar S Al-Attas, Lotfi S Bindahman, Majed S Alokail, Khalid M Alkharfy, Hossam M Draz, Sobhy Yakout, Philip G McTernan, Shaun Sabico, George P Chrousos.   

Abstract

BACKGROUND: The hallmark of vascular inflammation is the recruitment of circulating leucocytes, primarily monocytes, macrophages and T lymphocytes, into the vascular wall; however, the link between monocyte/macrophage activation and hypertension has not been established as yet. In this study, we determined how sCD163, a monocyte/macrophage soluble scavenger receptor and immunomodulator, relates to arterial blood pressure (BP) in hypertensive Saudi individuals.
MATERIALS AND METHODS: A total of 90 (30 non-hypertensive obese, 30 hypertensive obese and 30 lean normotensive controls) adult Saudi subjects, aged 40-60 years, participated in this cross-sectional study. Serum fasting blood glucose, triglycerides, total cholesterol, HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), leptin, adiponectin, resistin, insulin, tumour necrosis factor-alpha (TNF-α), PAI-1, angiotensin II, high-sensitivity C-reactive protein (hsCRP) and sCD163 were measured in all subjects studied.
RESULTS: sCD163 concentrations were significantly increased in obese hypertensive patients compared to controls (P=0.016). Positive correlations between sCD163 and body mass index (BMI) (r=0.27, P=0.01), systolic BP (r=0.25, P=0.01), diastolic BP (r=0.33, P=0.001), LDL-C (r=0.21, P=0.04), TNF-α (r=0.23, P=0.02) and hsCRP (r=0.33, P=0.008) were observed. Positive correlations between sCD163 and diastolic BP (r=0.23, P=0.04) and LDL-C (r=0.22, P=0.03) remained significant after controlling for BMI.
CONCLUSIONS: Taken together, these data demonstrate that the monocyte/macrophage activation-related sCD163 is positively associated with BMI and increased arterial BP with the elevation in diastolic BP being independent of the BMI.
© 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22946776     DOI: 10.1111/j.1365-2362.2012.02714.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

1.  The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.

Authors:  Crina Claudia Rusu; Simona Racasan; Ina Maria Kacso; Liviu Ghervan; Diana Moldovan; Alina Potra; Ioan Mihai Patiu; Cosmina Bondor; Mirela Gherman Caprioara
Journal:  Int Urol Nephrol       Date:  2015-10-03       Impact factor: 2.370

2.  The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function.

Authors:  Zhila Semnani-Azad; Philip W Connelly; Luke W Johnston; Ravi Retnakaran; Stewart B Harris; Bernard Zinman; Anthony J Hanley
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

Review 3.  Immunometabolism in obese asthmatics: are we there yet?

Authors:  Hashim A Periyalil; Peter G Gibson; Lisa G Wood
Journal:  Nutrients       Date:  2013-09-10       Impact factor: 5.717

4.  Increased macrophage activation marker soluble CD163 is associated with graft dysfunction and metabolic derangements in renal transplant recipients.

Authors:  Hayam El Aggan; Sabah Mahmoud; Heba El Shair; Hazem Elabd
Journal:  Biomed J       Date:  2020-10-01       Impact factor: 7.892

5.  Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk.

Authors:  Andrés Díaz-López; Mònica Bulló; Matilde R Chacón; Ramón Estruch; Joan Vendrell; Javier Díez-Espino; Montserrat Fitó; Dolores Corella; Jordi Salas-Salvadó
Journal:  Cardiovasc Diabetol       Date:  2014-02-24       Impact factor: 9.951

Review 6.  TWEAK: A New Player in Obesity and Diabetes.

Authors:  Joan Vendrell; Matilde R Chacón
Journal:  Front Immunol       Date:  2013-12-30       Impact factor: 7.561

7.  Visceral obesity is associated with increased soluble CD163 concentration in men with type 2 diabetes mellitus.

Authors:  Lars Peter Sørensen; Tina Parkner; Esben Søndergaard; Bo Martin Bibby; Holger Jon Møller; Søren Nielsen
Journal:  Endocr Connect       Date:  2015-03       Impact factor: 3.335

Review 8.  Clinical significance of sCD163 and its possible role in asthma (Review).

Authors:  Yue Zhi; Peng Gao; Xiuqin Xin; Wei Li; Lei Ji; Lin Zhang; Xueyang Zhang; Jie Zhang
Journal:  Mol Med Rep       Date:  2017-03-24       Impact factor: 2.952

9.  Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15-34 years of age: a prospective cohort study.

Authors:  My Samuelsson; Jonatan Dereke; Maria K Svensson; Mona Landin-Olsson; Magnus Hillman
Journal:  Diabetol Metab Syndr       Date:  2017-05-25       Impact factor: 3.320

10.  Soluble CD163 was linked to galectin-3, diabetic retinopathy and antidepressants in type 1 diabetes.

Authors:  Eva O Melin; Jonatan Dereke; Maria Thunander; Magnus Hillman
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.